BioNxt Solutions Announces Development of Sublingual Thin-Film for Semaglutide
VANCOUVER, BC / ACCESSWIRE / December 2, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, announces the development of a sublingual thin-film oral dissolvable film (ODF) for Semaglutide, internally identified as BNT24005. This innovative product is intended to address limitations of existing administration methods for a therapeutic developed by Novo Nordisk, with the aim of improving patient accessibility and convenience. This product is currently under development and remains subject to regulatory review and approval.
Semaglutide: A Proven Therapeutic Leader
Semaglutide, developed by Novo Nordisk and marketed under brand names such as Ozempic® and Wegovy®, has revolutionized treatment for Type 2 diabetes and obesity. By mimicking glucagon-like peptide-1 (GLP-1), it enhances insulin secretion, reduces appetite, and slows gastric emptying, offering powerful tools for glycemic control and weight management.
In 2023, Semaglutide generated over $14 billion in revenue globally, reflecting surging demand for effective diabetes and obesity treatments (The Washington Post).
The BioNxt Advantage
Despite Semaglutide's success, its injectable format presents barriers, including needle anxiety and challenges with long-term adherence. BioNxt's sublingual thin-film technology, BNT24005, offers a novel delivery system that aims to reduce these hurdles, improving the overall patient experience.
Key benefits of the sublingual thin-film include:
Needle-Free Convenience: A painless and discreet alternative to injections.
Rapid Absorption: Direct sublingual delivery for faster therapeutic action.
Enhanced Bioavailability: Reduced enzymatic degradation compared to traditional oral routes.
Improved Patient Compliance: A portable, user-friendly format designed to encourage long-term adherence.
This next-generation delivery method has the potential to address unmet needs in diabetes and obesity care, aligning with global trends favoring patient-centric solutions.
Significant Market Opportunity
The global burden of diabetes and obesity underscores the growing need for innovative treatments. According to the International Diabetes Federation, over 537 million adults worldwide are living with diabetes, and the prevalence of obesity continues to rise.
Semaglutide's existing market success highlights the potential for innovative delivery systems. BioNxt aims to address patient challenges while adhering to stringent regulatory and intellectual property standards.
Strategic Development and Patent Positioning
BioNxt's thin-film innovation focuses on enhancing drug delivery methods without infringing on existing molecule patents. The product leverages a strategy centered on patentable administration improvements, respecting the intellectual property of Novo Nordisk.
BioNxt's Broader Pipeline of Innovations
The Semaglutide thin-film, BNT24005, is part of BioNxt's broader portfolio of advanced drug delivery technologies, targeting therapeutic areas such as neurodegenerative diseases, metabolic disorders, and other high-need markets. BioNxt's platforms include sublingual thin-films, transdermal patches, and enteric-coated oral tablets, all designed to enhance patient outcomes and healthcare accessibility.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablet)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 780-818-6422
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements regarding the development, potential benefits, and commercialization of BioNxt's sublingual thin-film product for Semaglutide. These statements are based on current expectations and projections about future events but involve risks and uncertainties outside of the Company's control. Risks include challenges in obtaining regulatory approvals, potential intellectual property disputes or claims from third parties, and uncertainties associated with product development, manufacturing, and clinical validation. Additional risks include the potential for limited market acceptance of the sublingual thin-film technology and competitive pressures within the diabetes and obesity therapeutic sectors. Readers are cautioned that actual results may differ materially from those expressed in these forward-looking statements due to these and other factors. BioNxt Solutions Inc. undertakes no obligation to update forward-looking statements, except as required by applicable laws.
Trademarks: Trademarks Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S and are referenced in this document solely for informational and comparative purposes to contextualize the market landscape. BioNxt Solutions Inc. is neither affiliated with nor endorsed by Novo Nordisk A/S.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
BioNxt Solutions Inc.

Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
An Incredible KLAS Triple-Award Win for AGFA HealthCare!10.2.2025 09:00:00 CET | Press release
MORTSEL, BE / ACCESS Newswire / February 10, 2025 / AGFA HealthCare proudly celebrates a remarkable KLAS triple-win, securing two #1 Best in KLAS Awards for XERO® Viewer and VNA, alongside the KLAS Most Improved Software Product for 2025. "To receive a KLAS Award is one of the most notable wins for AGFA HealthCare, and a testament to the hard work we invest into our flagship platform. More importantly, it reflects the trust and recognition from our customers. Their success is our success, and to receive two such awards is simply breathtaking." - Nathalie McCaughley, President, AGFA HealthCare The Best in KLAS report recognizes software and service providers who excel in supporting healthcare professionals and patient care. Based on extensive customer feedback and evaluations, these awards highlight AGFA HealthCare's unwavering commitment to innovation and excellence. For 2025, AGFA HealthCare's Enterprise Imaging XERO® Viewer leads the Universal Viewer (Imaging) category for the second
Eviva Partners, a New Nonprofit Promoting Better Understanding of Medical Evidence, Exposes Role of Andrew Wakefield in the “Manufacture of Evidence” Leading Up to Robert F. Kennedy Jr’s Confirmation Hearings10.2.2025 07:50:00 CET | Press release
Introduces the concept of "Evidence Fluency" as a solution to the current crisis and a path towards improving healthcare overall NEW YORK CITY, NEW YORK / ACCESS Newswire / February 10, 2025 / Eviva Partners, a pioneering healthcare initiative founded by physician-scientist Alex Morozov, announced its launch today with an innovative mission to address critical gaps in healthcare delivery through "evidence fluency" - a new framework for understanding and communicating medical evidence. "The new US Administration is poised to have a dramatic impact on the integrity of scientific publications and medical evidence," said Alex Morozov, CEO and Founder. "An investigation over the past several days reveals a role of Andrew Wakefield in the "Manufacture of Evidence" leading up to Robert F. Kennedy Jr's Confirmation hearings. Wakefield 30 years ago was paid by another anti-vaccine lawyer, Richard Barr, to manufacture a study through research fraud showing a link between vaccines and autism. His
Registration Now Open for World of Coffee 2025 in Geneva: The Premier Event for Coffee Professionals6.2.2025 09:00:00 CET | Press release
Join Over 13,000 Attendees and 430+ Exhibitors at Europe's Largest Specialty Coffee Trade Show GENEVA, SWITZERLAND / ACCESS Newswire / February 6, 2025 / World of Coffee, the essential event for coffee professionals, enthusiasts, and innovators from around the globe will have a 2025 edition in Geneva, Switzerland, at the Palexpo SA, June 26-28. Following the record-breaking success of World of Coffee in Copenhagen, this flagship coffee trade show is set to welcome over 13,000 coffee professionals from 160+ countries for three days of business, networking, and education. Produced by the Specialty Coffee Association (SCA), the trade show and conference are proudly supported by Host Sponsor BTW Water + More; Platinum Sponsor Barista Attitude; Diamond Sponsor Nestlé Professional; and Gold Sponsor Alpro. Café de Colombia will be featured as the Portrait Country with unique cultural activations, and a pop-up café experience. "Geneva is the ideal location for hosting our flagship European tra
U.S.-Based Blockchain Kadena and Croatian Football Federation (HNS) Partner to Revolutionize Fan Engagement6.2.2025 09:00:00 CET | Press release
The Agreement Includes Regular Season Play as Well as the 2026 FIFA World Cup 2026 and UEFA EURO 2028 NEW YORK CITY, NEW YORK / ACCESS Newswire / February 6, 2025 / Kadena, the industry leader in scalable blockchain technology, and the Croatian Football Federation (HNS) have announced a groundbreaking partnership to provide a seamless digital fan engagement experience to Croatian national team fans. This partnership will encompass major global football events through 2028, including the 2026 FIFA World Cup and 2028 UEFA Euro Cup.Kadena and The Croatian Football Federation Enter Partnership to Revolutionize Fan Engagement This collaboration will introduce high-visibility activations, access to VIP experiences, and the migration of the HNS ERC-20 fan token, VATRENI, from Polygon to Kadena via the Kinesis Bridge. "The goal with the [VATRENI] token is to push the boundaries of traditional fan engagement opportunities of the past and introduce more of a future-focused fan experience. We're
Preservica Delivers Actionable Trusted Long-Term Data with New Innovations in AI and Active Digital Preservation6.2.2025 09:00:00 CET | Press release
BOSTON, MA AND OXFORD, UK / ACCESS Newswire / February 6, 2025 / Preservica, the industry leader in Active Digital Preservation™ archiving, today unveiled a series of groundbreaking innovations to its pioneering platform. These enhancements further simplify and automate the complex task of preserving critical long-term data, ensuring it remains instantly usable, reliable, and trusted for compliance and emerging AI use. With up to a third of digital content needing to be retained long-term (more than 7 years) according to IDC, unreadable or lost data from poor retention policies, obsolete file formats and accidental or intentional change or deletion is not only a serious compliance, reputational and legal risk but also impacts an organization's ability to leverage AI for value creation and process automation. "As digital content continues to rapidly grow in volume and complexity, having a robust and secure foundation of instantly useable, reliable and trusted long-term data has become a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom